Catalent, Inc.
(NYSE : CTLT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corp. Plc
11.77%24.021.7%$252.26m
VRXValeant Pharmaceuticals International, Inc.
2.63%28.4814.1%$167.58m
BHCBausch Health Cos., Inc.
2.63%28.480.0%$119.07m
GWPHGW Pharmaceuticals Plc
2.26%108.416.2%$82.69m
MDCOThe Medicines Co.
2.14%51.9820.2%$80.72m
JAZZJazz Pharmaceuticals Plc
3.60%138.642.3%$64.51m
SAGESAGE Therapeutics, Inc.
3.93%146.328.6%$52.92m
PRGOPerrigo Co. Plc
2.83%49.406.8%$50.04m
ENDPEndo International Plc
8.89%4.538.8%$45.54m
UTHRUnited Therapeutics Corp.
1.01%90.4314.3%$39.52m
HZNPHorizon Therapeutics Plc
1.51%30.266.6%$38.93m
ICPTIntercept Pharmaceuticals, Inc.
-0.96%82.2516.9%$38.81m
ICLRICON plc
1.42%154.594.2%$37.69m
CTLTCatalent, Inc.
2.65%50.412.4%$31.87m
ARGXargenx SE
1.45%139.370.0%$26.47m

Company Profile

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies; Biologics and Specialty Drug Delivery; Oral Drug Delivery; and Clinical Supply Services. The Softgel Technologies segment formulate, develop, and manufacture services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and manufacture services for blow-fill-seal unit doses, prefilled syringes, vials, and cartridges; analytical development and testing services for large molecules; inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays. The Oral Drug Delivery segment focuses in the formulation development and manufacturing technologies, and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules, and sachet products. The Clinical Supply Services segment includes packaging, labeling, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in April 2007 and is headquartered in Somerset, NJ.